Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases

L. Himelstein, Andrew; C. Foster, Jared; Khatcheressian, James; D. Roberts, John; K. Seisler, Drew; J. Novotny, Paul; Qin, Rui; S. Go, Ronald; S. Grubbs, Stephen; L. O’Connor, Tracey; R. Velasco, Mario; Weckstein, Douglas; M. O’Mara, Ann; L. Loprinzi, Charles; L. Shapiro, Charles

doi:10.1001/jama.2016.19425

Public

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases

Published in JAMA • Jan 3, 2017

Authors:

Andrew L. Himelstein

Jared C. Foster

James Khatcheressian

Abstract

Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain. Objective: To determine whether zoledronic acid administered every 12 weeks i...

Subject

Medicine

Zoledronic acid

Bone pain

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!